Actively Recruiting
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Led by Yale University · Updated on 2026-05-12
10
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.
CONDITIONS
Official Title
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form
- Willingness to comply with all study procedures and availability for up to 6 months (3-month treatment plus 3-month follow-up)
- Age 18 years or older
- Body Mass Index (BMI) of 30 or higher, or BMI of 27 or higher with a medical comorbidity, and BMI no greater than 50 kg/m2
- Had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years
- Meet current DSM-5 criteria for Alcohol Use Disorder
- Otherwise healthy without uncontrolled medical problems as determined by study physicians
- Able to read, understand, and write English sufficiently to complete study materials
- For females of reproductive potential: use of highly effective contraception and agreement to use it during the study
You will not qualify if you...
- Myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within 60 days before screening
- History or presence of chronic or recurrent pancreatitis
- History of malignant tumors within 5 years before screening
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- Currently using weight loss medications or other GLP-1 receptor agonists
- Allergy or sensitivity to Semaglutide
- Psychiatric conditions requiring hospitalization or intensive treatment (e.g., bipolar disorder, psychosis, severe depression)
- Untreated hypertension with high blood pressure or heart rate above specified limits
- Current uncontrolled hypertension
- Current uncontrolled Type I or II diabetes
- Untreated hypothyroidism with abnormal TSH levels
- Active gallbladder disease
- History of severe kidney, liver, neurological, chronic lung disease, or other unstable medical disorders
- Substance use disorder (except cannabis or tobacco) within past 12 months
- Currently receiving treatment for Alcohol Use Disorder or actively trying to quit alcohol
- Participating in another clinical study with investigational or non-investigational drugs or devices
- Pregnant, breast-feeding, or not using reliable birth control
- Active suicidal or homicidal thoughts
- Any other condition that may jeopardize safety or study compliance as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yale School of Medicine
New Haven, Connecticut, United States, 06520
Actively Recruiting
Research Team
V
Valentina Ivezaj, PhD
CONTACT
C
Caitlin Smith, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here